SCHEMBL23833746

SCHEMBL23833746

COc1ccc(NC(=O)c2nnc(-c3ccccc3)[nH]2)cc1S(=O)(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
GAA P10253 2/20 0.53
ALPL P05186 1/20 0.52
CPT1A P50416 1/20 0.50
CPT1B Q92523 1/20 0.50
LMNA P02545 5/20 0.49
IDH1 O75874 4/20 0.49
POLB P06746 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TNF P01375 1/20 0.49
NOD2 Q9HC29 1/20 0.49
NOD1 Q9Y239 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
ALDH1A1 P00352 1/20 0.48
ALOX12 P18054 1/20 0.48
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
PTPN2 P17706 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30199611 1.00 MAPT (0.53) MAPTMEN1KMT2AGAAALPL
SCHEMBL23846606 0.86 IDH1 (0.52) MAPTIDH1
SCHEMBL25755146 0.85 ALPL (0.54) MAPTMEN1KMT2AGAAALPL
SCHEMBL25757314 0.81 PTPN2 (0.57) MAPTMEN1KMT2AGAAALPL
SCHEMBL23846622 0.80 MEN1 (0.53) MAPTMEN1KMT2AGAAALPL
SCHEMBL23846617 0.79 MAPT (0.56) MAPTMEN1KMT2AGAAALPL
SCHEMBL25755180 0.78 ALPL (0.54) MAPTMEN1KMT2AGAAALPL
SCHEMBL23846390 0.78 MAPT (0.62) MAPTMEN1KMT2AGAAALPL
SCHEMBL23846615 0.78 MEN1 (0.52) MAPTMEN1KMT2AGAAALPL
SCHEMBL23833747 0.78 IDH1 (0.55) MAPTMEN1KMT2AGAAALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
EP-4121029-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF Amathus Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188880-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed
WO-2021188880-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 MAPT 89/4885MEN1 3902/4885KMT2A 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.